

### ***2.1.4 Use of Placebo in Clinical Practice***

A placebo is a substance provided to a patient that the physician believes has no specific pharmacological effect on the condition being treated. The use of placebo, when consistent with good medical care, is distinct from interventions that lack scientific foundation.

A placebo may still be effective if the patient knows it will be used but cannot identify it and does not know the precise timing of its use. In the clinical setting, the use of a placebo without the patient's knowledge may undermine trust, compromise the patient-physician relationship, and result in medical harm to the patient.

Physicians may use placebos for diagnosis or treatment only if they:

- (a) Enlist the patient's cooperation. The physician should explain that it can be possible to achieve a better understanding of the medical condition by evaluating the effects of different medications, including the placebo.
- (b) Obtain the patient's general consent to administer a placebo. The physician does not need to identify precisely when the placebo will be administered. In this way, the physician respects the patient autonomy and fosters a trusting relationship, while the patient may still benefit from the placebo effect.
- (c) Avoid giving a placebo merely to mollify a difficult patient. Giving a placebo for such reasons places the convenience of the physician above the welfare of the patient. Physicians can produce a placebo-like effect through the skillful use of reassurance and encouragement, thereby building respect and trust, promoting the patient-physician relationship, and improving health outcomes.

***AMA Principles of Medical Ethics: I,III,V,VIII***

*Background report(s):*

CEJA 3-A-16 Modernized *Code of Medical Ethics*

CEJA 2-I-06 Placebo use in clinical practice

**2.1.4 Use of Placebo in Clinical Practice**

A placebo is a substance provided to a patient that the physician believes has no specific pharmacological effect on the condition being treated. *The use of placebo, when consistent with good medical care, is distinct from interventions that lack scientific foundation. [New content clearly distinguishes placebo from invalid, scientifically unfounded interventions.]*

A placebo may still be effective if the patient knows it will be used but cannot identify it and does not know the precise timing of its use. In the clinical setting, the use of a placebo without the patient's knowledge may undermine trust, compromise the patient-physician relationship, and result in medical harm to the patient.

Physicians may use placebos for diagnosis or treatment only if they:

- (a) Enlist the patient's cooperation. The physician should explain that it can be possible to achieve a better understanding of the medical condition by evaluating the effects of different medications, including the placebo.
- (b) Obtain the patient's general consent to administer a placebo. The physician does not need to identify precisely when the placebo will be administered. In this way, the physician respects the patient autonomy and fosters a trusting relationship, while the patient may still benefit from the placebo effect.
- (c) Avoid giving a placebo merely to mollify a difficult patient. Giving a placebo for such reasons places the convenience of the physician above the welfare of the patient. Physicians can produce a placebo-like effect through the skillful use of reassurance and encouragement, thereby building respect and trust, promoting the patient-physician relationship, and improving health outcomes.

***AMA Principles of Medical Ethics: I,III,V,VIII***

# REPORT OF THE COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS\*

CEJA Report 2-I-06

Subject: Placebo Use in Clinical Practice

Presented by: Robert M. Sade, MD, Chair

Referred to: Reference Committee on Amendments to Constitution and Bylaws  
(Francis X. Van Houten, MD, Chair)

---

## 1 INTRODUCTION

2  
3 The use of placebos in research has received much more attention than has their use in clinical  
4 practice. This report is intended to guide physicians' clinical use of placebos in ways that respect  
5 patients' autonomy by allowing them to participate actively in the medical decision-making  
6 process.

7  
8 For the purposes of this report, a placebo is defined as a substance that the physician believes has  
9 no known specific pharmacological activity against the condition being treated. Placebos can be  
10 therapeutically beneficial to some patients, when they give rise to the so-called "placebo effect."<sup>1</sup>  
11 In general, this refers to a change in the patient's condition that is attributable to the symbolic  
12 aspects of the overall care, rather than the medicinal qualities of the substance prescribed by the  
13 physician.<sup>1,2</sup> Although there is some debate as to the origins of the placebo effect,<sup>3,4</sup> much has been  
14 learned in recent years regarding its anatomical and physiological foundations.<sup>5</sup>

## 16 ETHICALLY APPROPRIATE PLACEBO USE

17  
18 Physicians administer placebos because they might relieve symptoms causing distress to their  
19 patients.<sup>6</sup> Historically, physicians used placebos without patients' knowledge, at a time when they  
20 had great latitude in providing treatment without a patient's consent if they believed the  
21 intervention to be medically indicated.<sup>7</sup> Accordingly, placebos often were used to relieve pain or  
22 other complaints that appeared to have no objective medical explanation.<sup>6,8</sup> Such use of placebos  
23 could convey benefits derived from the placebo effect or from the symbolic affirmation of  
24 physicians' willingness to help their patients.<sup>9</sup>

25  
26 The deception associated with placebo use, however, is now widely viewed as problematic because  
27 it directly conflicts with contemporary notions of patient autonomy and the practice of shared

---

\* Reports of the Council on Ethical and Judicial Affairs are assigned to the reference committee on Constitution and Bylaws. They may be adopted, not adopted, or referred. A report may not be amended, except to clarify the meaning of the report and only with the concurrence of the Council.

1 decision-making.<sup>7,10</sup> Today, if physicians attempt to deceive patients by representing placebos as  
2 pharmacologically active medications, they risk undermining their patients' trust.<sup>7,10</sup> Loss of trust  
3 is a serious consequence because it is a foundational component of the patient-physician  
4 relationship.<sup>10</sup> If trust is undermined, patients may be less satisfied with their physicians, and  
5 therefore less likely to consult them when making health-related decisions.<sup>11</sup> Moreover, patients  
6 may not adhere to treatment recommendations when trust in their physician has been compromised,  
7 thereby adversely affecting patients' overall health outcomes.<sup>12,13,14</sup>

8  
9 Deceptive use of placebos poses other potential harms to patients, as well. For example, this use of  
10 placebos may mask and potentially delay the treatment of medical conditions.<sup>15</sup> Furthermore, some  
11 patients may encounter adverse side effects resulting from placebo use, an occurrence known as  
12 the "nocebo phenomenon."<sup>16</sup>

13  
14 Ultimately, the deceptive use of placebos is not ethically acceptable because it may harm patients  
15 to a greater degree than it helps them. This is particularly true in cases where placebos are utilized  
16 to serve the convenience of the physician rather than to promote patient welfare. Perhaps the most  
17 pernicious use of placebos is for mollifying a patient who is demanding, displays a difficult  
18 personality, or has a complex problem that has become frustrating to the physician. Placebos  
19 should never be used in this way because it is fundamentally inconsistent with physicians'  
20 professional obligations to promote patients' welfare and respect patient autonomy.

21  
22 In some instances, it may be most appropriate to forego the use of placebos altogether. Several  
23 studies have described placebo-like effects that lead to better health outcomes when physicians are  
24 able to comfort and reassure patients presenting with symptoms that do not appear to have a clear  
25 medical basis.<sup>6,17</sup> This seems to work best when physicians establish partnerships with patients that  
26 are built on respect and trust, and encourage adherence to treatment plans.<sup>2,18</sup>

27  
28 In other instances, physicians may utilize placebos within their clinical practice without relying on  
29 the act of deception. In these cases, physicians should make decisions regarding the use of  
30 placebos in partnership with their patients.<sup>19,20</sup> For example, a physician could explain to a patient  
31 that a more certain diagnosis or better understanding of his or her condition could be achieved by  
32 evaluating the effects of different types of medication, including one that is not pharmacologically  
33 active, namely, a placebo.<sup>21</sup> By obtaining the patient's cooperation in this manner, the physician  
34 need neither identify which medication is the placebo nor seek specific consent immediately before  
35 its administration.<sup>22</sup> This example of shared decision-making demonstrates an approach that  
36 respects patient autonomy and fosters trust within the patient-physician relationship. Moreover, the  
37 authorized use of placebos is not expected to significantly diminish their clinical effectiveness as  
38 research suggests that little variation in clinical outcomes is observed between patients who are  
39 informed that they are to be treated with placebos and patients who were administered placebos in  
40 a deceptive manner.<sup>23,24,25</sup>

1 When physicians are faced with significant clinical or diagnostic uncertainty, the authorized use of  
2 placebos may prove particularly valuable for conducting single-patient controlled studies, known  
3 as a “N-of-1” trials.<sup>26</sup> In these trials, a disease-specific intervention and a placebo are alternated  
4 through several treatment cycles; the duration of each cycle depending on the nature of the  
5 disease.<sup>27</sup> Such studies can be single-blinded, in which only the patient is unaware of which drug is  
6 being administered, or they can be double-blinded, in which the assignment of treatment is  
7 managed by a third person, such as a pharmacist, so neither patient nor physician knows which  
8 medication is in use. In either case, the patient keeps a detailed journal of the waxing and waning  
9 of symptoms. At the study’s conclusion, the physician can differentiate between benefits  
10 attributable to the pharmacologically active drug and to the placebo.<sup>28</sup> Throughout this process, the  
11 patient’s progress should be monitored and the placebo discontinued if the active agent is found  
12 clearly to be more effective.<sup>8</sup>

13

#### 14 CONCLUSION

15

16 Placebos are substances that the physician believes have no specific pharmacological activity  
17 against the condition being treated. They may be used in clinical practice to determine a diagnosis  
18 or appropriate treatment in the face of clinical uncertainty. Physicians must avoid deception when  
19 administering placebos by informing the patient that a placebo may be used.

20

#### 21 RECOMMENDATIONS

22

23 The Council on Ethical and Judicial Affairs recommends that the following be adopted and the  
24 remainder of this report be filed:

25

26 A placebo is a substance provided to a patient that the physician believes has no specific  
27 pharmacological effect upon the condition being treated. In the clinical setting, the use of a  
28 placebo without the patient’s knowledge may undermine trust, compromise the patient-  
29 physician relationship, and result in medical harm to the patient.

30

31 Physicians may use placebos for diagnosis or treatment only if the patient is informed of and  
32 agrees to its use. A placebo may still be effective if the patient knows it will be used but  
33 cannot identify it and does not know the precise timing of its use. A physician should enlist  
34 the patient’s cooperation by explaining that a better understanding of the medical condition  
35 could be achieved by evaluating the effects of different medications, including the placebo.  
36 The physician need neither identify the placebo nor seek specific consent before its  
37 administration. In this way, the physician respects the patient’s autonomy and fosters a  
38 trusting relationship, while the patient still may benefit from the placebo effect.

39

40 A placebo must not be given merely to mollify a difficult patient, because doing so serves the  
41 convenience of the physician more than it promotes the patient’s welfare. Physicians can  
42 avoid using a placebo, yet produce a placebo-like effect through the skillful use of reassurance

1           and encouragement. In this way, the physician builds respect and trust, promotes the patient-  
2           physician relationship, and improves health outcomes.

3

4 (New HOD/CEJA Policy)

Fiscal Note: Staff cost estimated at less than \$500 to implement.

## ACKNOWLEDGMENTS

The Council gratefully acknowledges the following individuals and organizations for their efforts to review previous drafts of this Report:

American Academy of Pain Medicine Council on Ethics; Paul Appelbaum, MD, American Psychiatric Association Council on Psychiatry and Law; Perry Fine, MD, Professor of Anesthesiology, University of Utah; Richard Milone, MD, Past Chair, American Psychiatric Association Ethics Committee; Laura Roberts, MD, Chair, American Psychiatric Association Task Force to Update the Ethics Annotation.

## REFERENCES

- <sup>1</sup> Brody H. *Placebo*. In: Encyclopedia of Bioethics. Reich WT. Ed. New York: Simon & Schuster Macmillan, 1995. 1951-3.
- <sup>2</sup> Brody, H. The placebo response: Recent research and implications for family medicine. *Journal of Family Practice*. 2000;49(7):649-54.
- <sup>3</sup> Hróbjartsson A, Gøtzsche PC. An analysis of clinical trials comparing placebo with no treatment. *N Engl J Med*. 2001;344(21):1594-602
- <sup>4</sup> Glausiusz J. Is the placebo effect a myth? *Discover*. 2001;September:14
- <sup>5</sup> Irizarry K, Licinio J. An explanation for the placebo effect? *Science*. 2005;307(5714):1411-2.
- <sup>6</sup> Thoms, K. The placebo in general practice. *Lancet*. 1994;334:1066-67.
- <sup>7</sup> Kleinman I, Brown P, Librach L. Placebo *Pain* Medication: Ethical and Practical Considerations. *Arch Fam Med*. 1994; 3: 453-457.
- <sup>8</sup> Lichtenberg, P., Heresco-Levy, U., Nitzan, U. The ethics of the placebo in clinical practice. *J Med Ethics*. 2004;30:551-4.
- <sup>9</sup> Spiro, H. Clinical reflections on the placebo phenomenon. In: *The Placebo Effect, An Interdisciplinary Exploration*. Harrington, A., ed Cambridge: Harvard University Press. 1997. 37-55.
- <sup>10</sup> CEJA Opinion E-10.01, "Fundamental Elements of the Patient-Physician Relationship"
- <sup>11</sup> Beauchamp, T, Childress, J. *Principles of Biomedical Ethics, 5<sup>th</sup> Edition*. New York: Oxford University Press. 2001.
- <sup>12</sup> Levy, D. White doctors and black patients: influence of race on the doctor-patient relationship. *Pediatrics*. 1986;75:639-43.
- <sup>13</sup> Kao, A., Green, D., Zaslavsky, A., Koplan, J., Cleary, P. The relationship between method of physician payment and patient trust. *JAMA*. 1998; 280:1708-14
- <sup>14</sup> Mechanic, D., The functions and limitations of trust in the provision of medical care. *J Health Polit Policy Law*. 1998;23:661-86
- <sup>15</sup> Hébert P, Hoffmaster B, Glass C, Singer P. Bioethics for clinicians: Truth telling. *Can Med Assoc J*. 1997; 156:225-228.
- <sup>16</sup> Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. *JAMA*. 2002;287(5):622-627
- <sup>17</sup> Thomas, K. General practice consultations: is there any point in being positive? *BMJ*. 1987;294:1200-02.
- <sup>18</sup> Egbert, L., Battit, G., Welch, C., Bartlett, M. Reduction of post-operative pain by encouragement and instruction of patients. *NEJM*. 1964;270:825-7.
- <sup>19</sup> Opinion E-10.015, "The Patient-Physician Relationship"
- <sup>20</sup> Opinions E-10.01, "Fundamental Elements of the Patient-Physician Relationship," and E-8.08, "Informed Consent."

© 2006 American Medical Association. All Rights Reserved.

**THIS DOCUMENT MAY NOT BE CITED, REPRODUCED OR  
DISTRIBUTED WITHOUT EXPRESS WRITTEN PERMISSION**

- <sup>21</sup> Barry, M. Involving Patients in Medical Decisions: How Can Physicians Do Better? *JAMA*. 1999;282: 2356–57.
- <sup>22</sup> Beauchamp, T, Childress, J. *Principles of Biomedical Ethics, 5<sup>th</sup> Edition*. New York: Oxford University Press. 2001. 84-86.
- <sup>23</sup> Amanzion, M, Benedetti, F. Neuropharmacological dissection of placebo analgesia: expectation activated opioid systems versus conditioning activated specific systems. *J Neurosci*. 1999;19:484-94.
- <sup>24</sup> Park, LC., Covi, L. Non-blind placebo trial. An exploration of neurotic patients' responses to placebo when its inert content is disclosed. *Arch Gen Psychiatry*. 1965;12:336-45.
- <sup>25</sup> Holmes D, Bennett D. Experiments to answer questions raised by the use of deception in psychological research. I. Role playing as an alternative to deception. II. Effectiveness of debriefing after a deception. III. Effect of informed consent on deception. *J Pers Soc Psychol*. 1974;29: 358–367
- <sup>26</sup> Irwig, L, Glasziou, P., March, L. Ethics of N-of-1 Trials. *Lancet*. 1995;345:469.
- <sup>27</sup> Nikles, C., Clavarino, A., Del Mar, C. Using n-of-1 trials as a clinical tool to improve prescribing. *Br J Gen Pract*. 2005;55(512):175-80.
- <sup>28</sup> Price, JD, Evance, JG. N-of-1 randomize controlled trials ('N-of-1 trials')" singularly useful in geriatric medicine. *Age and Aging*. 2002; 31:227-32.